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OBJECTIVE: To investigate the effect of pioglitazone on inflammation-induced
bone loss and changes in bone microarchitecture in rats with adjuvant-induced
arthritis (AIA), focusing on the contribution of interleukin-17 (IL-17) and the
balance of RANKL and osteoprotegerin (OPG).
METHODS: Male Lewis rats sensitized with Freund's complete adjuvant were
treated orally for 21 days with 30 mg/kg/day of pioglitazone or vehicle. Arthritis
severity was evaluated by clinical and histologic examination. Bone mineral density
(BMD) was assessed by dual x-ray absorptiometry. The therapeutic effect of
pioglitazone on changes of the bone architecture was determined by micro-
computed tomography (micro-CT). Levels of RANKL, OPG, and IL-17 were
determined by serum immunoassay and by synovial tissue immunohistochemistry.
Messenger RNA for IL-17 and retinoic acid receptor-related orphan nuclear
receptor γt (RORγt) was evaluated by quantitative reverse transcription-
polymerase chain reaction and IL-17 promoter activity by gene-reporter assay.
RESULTS: Micro-CT analysis revealed that pioglitazone treatment reduced
arthritis severity and bone erosion scores and increased BMD in comparison to
vehicle treatment. Cortical bone thickness was preserved, although the major
beneficial effect of pioglitazone was on indices of the trabeculae, especially
trabecular separation. Pioglitazone reduced the ratio of RANKL to OPG, in both the
serum and the inflamed synovium. Circulating levels of IL-17 were significantly
reduced by pioglitazone treatment, as were the percentages of IL-17-positive cells,
mainly polymorphonuclear cells, in the inflamed synovium. Induction of IL-17 was
strictly dependent on the binding of RORγt to IL-17 promoter, and lentiviral
overexpression of peroxisome proliferator-activated receptor γ (PPARγ) reduced
the expression of RORγt.
CONCLUSION: Pioglitazone decreased the level of inflammatory bone destruction
and protected the bone microarchitecture in rats with AIA by controlling the
circulating and local expression of IL-17, with a subsequent decrease in the
RANKL-to-OPG ratio. Along with the inhibition of RORγt expression after PPARγ
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